The Indian Patent Office (IPO) has revoked Novartis’ patent in India for its cardiac drug Vymada on the grounds of lack of novelty and inventive step. This decision not only impacts the pharmaceutical industry but also reinforces India’s jurisprudence on the delicate balance between rewarding innovation and safeguarding public health. Legal Basis for Revocation The...